• Earlier this month, Health Canada authorized Moderna to begin a Phase I clinical trial of its mRNA Bundibugyo Ebola vaccine candidate, while the U.S. FDA recently approved mFlusiva as the first mRNA flu vaccine for adults aged 50 and older, including accelerated approval for those 65 and above.
• This pairing of an early-stage Ebola program with full U.S. approval for an mRNA flu shot highlights how Moderna is extending its mRNA platform beyond COVID-19 into both seasonal and outbreak-driven vaccines.
• We’ll now examine how FDA approval of mFlusiva as an mRNA flu vaccine reshapes Moderna’s investment narrative and long-term positioning.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Moderna Investment Narrative Recap

To own Moderna today, you need to believe its mRNA platform can move from a concentrated, loss-making COVID business to a broader portfolio of approved, recurring products. The FDA’s green light for mFlusiva looks like the key near term catalyst, while the main risk remains whether new vaccines can offset revenue volatility and ongoing losses; the early stage Bundibugyo Ebola trial is scientifically interesting but not yet material to that near term equation.

Among recent developments, mFlusiva’s FDA approval stands out because it directly tests the core catalyst that many investors are watching: whether Moderna can turn its respiratory vaccine pipeline into meaningful, non COVID revenue. Bearish analysts, who were previously assuming only about US$2.5 billion in revenue by 2029, may revisit those expectations as real world flu uptake, pricing, and public attitudes toward mRNA become clearer.

Yet behind the excitement around mFlusiva, investors should be aware that concerns about vaccine pricing pressure and mRNA skepticism could still...

Moderna’s narrative projects $3.7 billion revenue and $695.7 million earnings by 2029.

Uncover how Moderna's forecasts yield a $44.25 fair value, a 31% downside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a far more cautious view than the consensus, assuming only about 3.5 percent annual revenue growth to roughly US$2.5 billion and continued losses, while worrying that pricing pressure and mRNA skepticism could limit how much impact approvals like mFlusiva and the Ebola program ultimately have on Moderna’s bottom line.

Explore 6 other fair value estimates on Moderna - why the stock might be worth less than half the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.